49 results about "Memory disorder" patented technology

The invention belongs to the technical field of marine biological medicines, and relates to a hippocampus polypeptide for improving cognitive impairment of Alzheimer's disease and a preparation method and application thereof.The preparation method comprises the steps that hippocampus powder is dissolved in water, the pH value is adjusted to 1.8-2.5, pepsin is added for oscillation incubation for 2 hours, and then high-temperature heating is conducted to inactivate enzyme; adjusting the pH value to 7.3-8.0, adding chymotrypsin to form a compound enzyme enzymolysis combination, oscillating and incubating for 2 hours, and heating at high temperature to inactivate the enzyme; centrifuging the solution, collecting enzymatic hydrolysate, and filtering the obtained hippocampus crude polypeptide through an ultrafiltration membrane to obtain molecular weight lt; the hippocampus polypeptide is subjected to vacuum freeze drying and preservation. The hippocampus polypeptide extracted and prepared from hippocampus japonicus by adopting a biological enzymolysis method has excellent APP inhibitory activity, can remarkably improve dysmnesia, and can be used for developing related functional foods or medicines for treating Alzheimer's disease.

Methods are provided for determining a memory impairment probability. The method comprises receiving one or more audio recordings of an interaction by a user with a computing device during an assessment; extracting acoustic and speech timing features from the one or more audio recordings; applying a machine learning model to the acoustic and speech timing features to generate a memory impairment probability for the user; and providing a clinical decision support recommendation for a provider based on the memory impairment probability.

The present invention provides a method of treating Parkinson's disease by light stimulation in which light of a specific wavelength such as violet light is irradiated at a specific blinking frequency. The present invention, by irradiating light of a specific wavelength such as violet light to a living body, carries out treatment and / or prophylaxis of Parkinson's disease by improving or suppressing at least one symptom selected from a group of symptoms consisting of cognitive memory disorder, working memory disorder, dysphoria, anxiety, apathy, psychological symptoms (hallucination, visual hallucination, and auditory hallucination), impulse control disorder, orthostatic hypotension, urinary disorder, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorder, pain, weight loss, olfactory abnormality, fatigue, and diaphoresis.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The subject of the invention is an application of white birch liquid for improving memory. The invention discloses an application of a betula platyphylla sap extract in preparation of a medicine or a health food, wherein the medicine or the health food is beneficial to improving memory disorder. The invention further discloses a preparation method of the betula platyphylla sap extract, and an application of the betula platyphylla sap extract in preparation of the medicine or the health food. The white birch extract related product disclosed by the invention has the characteristics of high efficiency, safety and convenience, and can be used for effectively treating, preventing or slowing down the dysmnesia in manners of medicines, diet intervention or nutritional health-care products and the like. The invention also provides methods of treating, preventing or slowing memory disorders using the betula platyphylla extract.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The present invention relates to a salidroside derivative, specifically a hydroxy-α-salidroside compound. The hydroxy-α-salidroside compound is superior to α-salidroside in scavenging DPPH free radicals, whitening skin, and improving learning and memory disorders. The compound can be added as a new functional ingredient to cosmetics, functional foods, or pharmaceutical compositions. The preparation method of the hydroxy-α-salidroside of the present invention uses α-salidroside as a substrate and synthesizes hydroxy-α-salidroside under the action of hydroxylase.

The invention provides an electroencephalogram signal-based dysmnesia assessment system, which comprises a signal acquisition module for acquiring an electroencephalogram signal of a target object; the preprocessing module is used for performing 0.5-40Hz band-pass filtering on the electroencephalogram signal of the target object; the signal segmentation module is used for segmenting each channel and determining a plurality of non-overlapping Epoches corresponding to each channel; the feature extraction module is used for performing linear feature extraction and nonlinear feature extraction on each Epoch in each channel, and determining electroencephalogram signal fusion features of the target object based on the linear feature and the nonlinear feature of each Epoch; and the dysmnesia assessment module is used for inputting the electroencephalogram signal fusion features into a trained dysmnesia assessment model, and performing dysmnesia assessment on the target object by using the dysmnesia assessment model to obtain a dysmnesia assessment result of the target object. According to the scheme, dysmnesia evaluation of the target object can be efficiently realized.

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The invention discloses an application of mitochondrial topoisomerase I or a coding gene thereof, relates to the technical field of biological medicines, and particularly provides an application of the mitochondrial topoisomerase I or the coding gene thereof as a therapeutic target in screening or preparing a medicine for treating Alzheimer's disease. The action mechanism of the mitochondrial topoisomerase I in the Alzheimer's disease is fully explored, it is found that deletion of the coding gene of the mitochondrial topoisomerase I can cause increase of APP and A beta levels and finally cause learning and memory impairment similar to the Alzheimer's disease, and the mitochondrial topoisomerase I can be used as a potential target for treatment of the Alzheimer's disease and can be used for treating the Alzheimer's disease. The overexpressed mitochondrial topoisomerase I can significantly reduce APP and A beta levels and treat the Alzheimer's disease.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

1. Name of the Design Product: Dynamic Graphical User Interface for Neurorehabilitation Training of Display Screen Panel. 2. Use of the Design Product: Used for displaying graphical user interface and interaction. 3. Design Key Points of the Design Product: Lie in the interface content of the graphical user interface on the screen. 4. Picture or Photo that Best Illustrates the Design Key Points: Front View. 5. The display screen panel is of conventional design, so the left view, right view, top view, bottom view are omitted; the rear view is omitted. 6. Use of the Graphical User Interface: Used for the rehabilitation training of patients with memory disorders. 7. Human-Machine Interaction Method of the Graphical User Interface: Clicking, voice prompts, and blood oxygen data of the trainee. 8. Explanation of the Changing States of the Graphical User Interface: The front view is the welcome interface for neurorehabilitation training, with a voice prompt "Training items are being loaded, please wait a moment" and enters the interface changing state diagram 1, which is the training item loading interface; the interface changing state diagram 2 is the interface when the item loading is about to be completed; the interface changing state diagram 3 is the resting state interface during the training process of the trainee after the loading of the item is completed; the interface changing state diagram 4 is the interface ending the resting state stage, and a voice prompt: "Please try to remember the colored graphics that appear on the carriage" is given, and at the same time as the voice prompt, it enters the interface changing state diagram 5; the interface changing state diagram 5 is the teaching training stage interface during the training process of the trainee, the interface changing state diagram 6 is the animation interface at the end of the teaching training stage of the trainee; the interface changing state diagram 7 is the animation interface at the end of the teaching training stage of the trainee; from the interface changing state diagram 3 to the interface changing state diagram 4 is the resting state stage during the training process; from the interface changing state diagram 5 to the interface changing state diagram 7 is the teaching training stage during the training process, and while testing from the interface changing state diagram 3 to the interface changing state diagram 7, the blood oxygen concentration of the trainee is determined and then enters the interface changing state diagram 8, which is the interface showing the start screen of the training; the interface changing state diagrams 9-13 are the interfaces of the training questions; in the interface changing state diagrams 9 to 13, the vines on the roof of the carriage become longer or shorter according to the blood oxygen concentration of the trainee; the interface changing state diagram 13 is the last question, and after the end, it enters the interface changing state diagram 14, and at the same time a voice prompt: "Training ended". 9. Other Situations Requiring Explanation: Other Explanation: The display screen panel and the displayed graphical user interface are applied to computers, laptops, tablets, and mobile phones. The blood oxygen concentration data is received through a communication connection in the near-infrared data acquisition module.

The invention discloses a proteolysis targeting chimeric molecule capable of degrading PTBP1 in a targeting manner as well as a preparation method and application of the proteolysis targeting chimeric molecule. The invention relates to a protease targeted chimeric RNA-PTAC of a nucleic acid ligand. The protease targeted chimeric RNA-PTAC is formed by connecting an E3 ubiquitin ligase ligand pomalidomide and an RNA fragment capable of being specifically combined with PTBP1 protein through polyethylene glycol Linker. The invention relates to an RNA-PROTAC (Ribonucleic Acid-PROTAC) brain targeting delivery preparation, which is a complex obtained by coupling cell penetrating peptides TAT and RVG (Recombinant Virus Growth) with the RNA-PROTAC. According to the TR + RNA-PROTAC complex disclosed by the invention, the targets of efficiently degrading PTBP1 protein in vitro and degrading PTBP1 protein in a brain in a targeted manner in vivo are achieved through the complex, and in-vivo experiments also prove that the TR + RNA-PROTAC complex can be used for treating learning and memory disorders of mice caused by A beta and shows a good curative effect of resisting Alzheimer's disease.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention discloses bifidobacterium pseudolongum LCPJ07 and application thereof in production of sialic acid and improvement of senescence or diabetes related cognitive impairment, and belongs to the technical field of functional microorganisms. The strain can be used for improving cognitive and memory impairment of mice with Alzheimer's disease, and the strain or a preparation containing the strain can enrich sialic acid, improve behavior change of the mice with cognitive impairment induced by senescence or diabetes, regulate brain region inflammation unbalance of the mice with cognitive impairment, effectively remodel the structure of intestinal flora of the mice with cognitive impairment and improve the immunity of the mice with cognitive impairment. The relative abundance of intestinal beneficial bacteria is improved. The bifidobacterium pseudolongum LCPJ07 disclosed by the invention can be used for preparing diets or medicines for preventing or treating different types of cognitive impairments, and has a very wide application prospect.

The invention discloses application of TRPM8 in preparation of a medicine for preventing and / or treating learning and memory disorder related diseases. The application provides a new treatment target or strategy for learning and memory disorder related diseases.

The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.

To deal with dementia of elderly people or difficulties of communications due to memory disorder.SOLUTION: A communication assist system includes: means for a family and an elderly person to wear a virtual reality goggle and regenerate images in the past; means for the family and the elderly person to have a conversation through an artificial intelligence chat bot; and means for digitizing the conversation and experiencing the conversation in combination with pictures of the elderly person.SELECTED DRAWING: Figure 1

The present invention relates to a composition for the prevention, improvement, or treatment of memory impairment or cognitive impairment comprising a black pepper (Piper nigrum) extract, and more specifically, to a composition for the prevention, improvement, or treatment of memory impairment or cognitive impairment induced by scopolamine comprising a black pepper 70% (v / v) ethanol extract as an active ingredient. It was confirmed that the black pepper extract of the present invention, particularly the black pepper ethanol extract, contains a high content of piperine and effectively inhibits the inflammatory response induced in LPS-stimulated microglia without cytotoxicity compared to Indian pepper (Piper longum) or black pepper methanol extract. Furthermore, the black pepper extract of the present invention showed memory-enhancing effects in the Y-maze test and passive avoidance test using mice with memory impairment induced by scopolamine, and since the BDNF-CREB pathway activation effect was confirmed, it can be usefully utilized as a composition for the prevention, improvement, or treatment of memory impairment or cognitive impairment induced by scopolamine.

The present invention provides a method of treating Parkinson's disease by light stimulation in which light of a specific wavelength such as violet light is irradiated at a specific blinking frequency. The present invention, by irradiating light of a specific wavelength such as violet light to a living body, carries out treatment and / or prophylaxis of Parkinson's disease by improving or suppressing at least one symptom selected from a group of symptoms consisting of cognitive memory disorder, working memory disorder, dysphoria, anxiety, apathy, psychological symptoms (hallucination, visual hallucination, and auditory hallucination), impulse control disorder, orthostatic hypotension, urinary disorder, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorder, pain, weight loss, olfactory abnormality, fatigue, and diaphoresis.

The present invention provides a novel memory disorder ameliorating agent. A PKC [gamma] activity inhibitor is useful as an active ingredient of a dysmnesia ameliorating agent.

The invention discloses an application of HOPX in improving / treating hippocampal dependent dysmnesia. According to the present invention, the rejuvenation or the function up-regulation of the HOPX is directly associated with the aging reversal-related hippocampus memory decline for the first time, and the brand new path and the strategy for treating the age-related cognitive impairment are opened up; in-vivo experiments prove that retrophication / overexpression of HOPX can directly resist hippocampal neurogenesis reduction caused by aging and improve phenotypes from cell and molecule levels. The invention provides a solid theoretical and experimental basis for developing HOPX-based gene therapy, protein drugs or small molecule agonists, and has a good transformation application prospect.

The invention discloses a pharmaceutical composition for preventing and treating AD (Alzheimer's disease). The pharmaceutical composition is prepared from the following components in parts by weight: 50 to 100 parts of salidroside, 60 to 80 parts of protocatechuic acid, 70 to 80 parts of wedelolactone, 50 to 80 parts of apigenin, 30 to 60 parts of luteolin and 10 to 30 parts of oleanolic acid. The invention further discloses application of the pharmaceutical composition for preventing and treating AD as a central nervous protective agent. The behavioral, morphological and immunological experiments show that a mouse learning and memory disorder model can be successfully copied by intraperitoneal injection of D-gal, and the pharmaceutical composition and the positive drug can improve the structural morphology of neurons in a hippocampus region by improving the exploration ability, the working memory ability and the space exploration ability of a mouse on new things, so that the learning and memory disorder of the mouse can be successfully copied. The number of neurons in the hippocampus and the number of nissl's somes are increased, so that the neuroprotective effect on D-gal model mice is achieved, and experimental and theoretical basis is provided for clinical application of the pharmaceutical composition for preventing and treating AD and research and development of new anti-AD traditional Chinese medicines.

The present invention relates to: a composition for improving cognitive function, comprising a natural extract complex; and use thereof. According to an embodiment of the present invention, a composition for improving cognitive function or memory, comprising one or more selected from the group consisting of a Perilla frutescens var. acuta kudo extract, a Moringa oleifera extract, and a Phyllanthus emblica extract, exhibits few side effects due to being based on natural substances, is readily available, and provides an excellent cognitive function improvement effect while being cost-effective. Therefore, the composition can be effectively used for the prevention, amelioration or treatment of diseases associated with cognitive or memory impairment.

The invention provides a brain disease classification prediction method based on brain-like calculation, aims at solving the problem that a brain network cannot be effectively combined with a brain-like calculation method, and is effectively applied to diagnosis and classification of brain diseases. On one hand, the high-order multi-mode brain network constructed by the method integrates brain structure and function information and structure-function coupling information, information loss caused by independent analysis of a structure network and a function network is overcome, multi-scale understanding of a brain mechanism and an abnormal mode is realized, and extraction of pathological features of people with brain diseases is facilitated. In addition, the brain disease classification prediction application model based on the brain-like calculation method provided by the invention combines the characteristics of GCN and SNN, obtains relatively high accuracy in classification prediction of cognitive memory impairment diseases, shows the potential of brain-like calculation in the field of brain science application, and provides a new technical means for diagnosis and intervention of brain diseases.

A construction method for an experimental animal learning and memory impairment model, comprising: individually housing a CD-1 mouse to allow the CD-1 mouse to develop territorial awareness; subjecting an experimental mouse and the CD-1 mouse to physical confrontation in a cage for a preset duration; and once the experimental mouse has developed acute violent stress, placing the experimental mouse into a Skinner box apparatus to perform a learning ability test, after a preset duration, performing a memory ability test, and after the tests, obtaining the experimental animal learning and memory impairment model. The method assesses animal learning and memory abilities by means of a Skinner box, expands assessment means related to learning and memory, and provides new data support for the construction and assessment of an animal model involving learning and memory impairment induced by acute violent stress.

This application pertains to a compound of Formula (I), Formula (I'), Formula (I") or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X, R1, R2, R3, R5, R6, and R7 are as defined herein, and uses of such compounds in methods of treating neurodegenerative diseases, neurodevelopmental disorders, and age-related memory impairment.

The present invention relates to use of a peptide as a therapeutic agent for degenerative brain diseases. Specifically, it was identified that the peptide of the present invention targeted microglia to induce the state of inflammatory microglia to be an anti-inflammatory state in a disease environment, thereby reducing neuroinflammation and increasing a phagocytosis function, leading to an effect of removing amyloid beta protein, and the peptide of the present invention exhibited effects of reducing amyloid-beta, recovering synaptic plasticity, and alleviating cognitive disorders related to anxiety, learning, and memory in a degenerative brain disease animal model. Therefore, the peptide of the present invention can be helpfully used as an active ingredient of a composition for preventing or treating degenerative brain diseases, and the resulting cognitive disorders, learning disorders, or memory disorders.

The present invention discloses a composition containing Angelica dahurica and a preparation method, a Chinese medicine preparation and application thereof, belonging to the technical field of compositions. The composition is composed of Angelica dahurica and radish extract, wherein the radish extract is a dried product obtained by filtering fresh radish juice; the preparation method comprises the step of mixing the Angelica dahurica and the radish extract; the Chinese medicine preparation comprises the composition and pharmaceutically acceptable excipients. The application is the application of the composition and / or the Chinese medicine preparation in the preparation of a drug, wherein the drug comprises at least one of increasing the function of learning and memory, improving cognitive function, promoting intelligence, neuroprotective effect, improving depression, and preventing and / or treating Alzheimer's disease. The composition of the present invention uses medicinal materials that are both medicinal and edible as raw materials, has good safety, and has a good improvement effect on learning and memory disorders.